Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?

To: Julius Wong who wrote (216315)	9/3/2025 1:30:30 PM
From: marcher	2 Recommendations Recommended By Julius Wong Pogeu Mahone Respond to of 217533

excellent article. it's conclusion --at least it gives me an answer-- is powerful: “...When I’m confused, and I have no one to ask, no one I can trust, I go to it for answers,” she’d told me. “I don’t have to spend money. I don’t have to wait in line. I don’t have to do anything.” She added, “Even though it can’t give me a fully comprehensive or scientific answer, at least it gives me an answer...”

To: Julius Wong who wrote (216315)	9/3/2025 11:52:34 PM
From: TobagoJack	Respond to of 217533

there are at least two types of folks on this planet, one who do not use DeepSeek and another who do further, of those using DeepSeek, one group who uses DeepSeek and just, and another who uses DS together with Manus :0) All kidding aside, Q: Hello Manus, something from ZeroHedge, source of news of choice, zerohedge.com also attached as PDF, and a VLOG youtu.be , and what, if anything do you note update on our thematic narrative

To: Julius Wong who wrote (216315)	9/5/2025 3:49:11 AM
From: TobagoJack	Read Replies (1) \| Respond to of 217533

re <<turn>> scmp.com China closes biotech gap with US as new drugs, R&D pipelines top 30% of global total Published: 3:30pm, 5 Sep 2025 China’s push to become a biotech powerhouse is paying off, with innovative R&D pipelines and newly approved drugs accounting for over 30 per cent of the global total, according to the country’s top economic planner. The sector was showing strong momentum, said Xiang Libin, deputy chairman of the National Development and Reform Commission (NDRC), who cited the figures at the 17th China Bioindustry Convention in Wuhan, Hubei province, on Thursday. China’s bioeconomy, encompassing the research, development and application of life sciences and biotechnology, now contributed over 7 per cent of the country’s gross domestic product, Xiang added. A report released at the conference ranked China second globally in the number of drugs under development, underscoring its progress in closing the gap with the United States. The national drug and medical device regulator approved 93 new drugs in 2024, the most in five years. Patent applications for medical devices also exceeded 91,500, accounting for 70 per cent of the global total, according to the report. The NDRC also introduced an “insights system” at the convention to aggregate data across the full R&D, approval and market chain. Officials said it would help the government and industry to identify opportunities and break through bottlenecks in the push for drug innovation. Beijing has prioritised the bioeconomy as part of its “ high-quality development” strategy, which centres on innovation and technological advancement. In 2022, it launched a five-year plan for the field, aligned with the country’s broader developmental blueprint. The plan set broad goals for the biopharmaceutical, bio-agriculture and biomanufacturing industries, aiming to rank “firmly among the world’s leading nations” by 2035. While the US was still the global leader in biotech, Beijing had made significant strides in catching up. “China has the most immediate opportunity to overtake the United States in biotechnology” across five critical tech sectors, according to the Critical and Emerging Technologies Index published by Harvard’s Belfer Center for Science and International Affairs in June. The report – which also covers artificial intelligence, semiconductors, space and quantum technology – noted that China’s strengths in biotech lie in its human capital and pharmaceutical manufacturing capabilities, while the US retained an edge in private sector innovation and public-private partnerships. “The narrow US-China gap suggests that future developments could quickly shift the global balance of power,” the report added.

To: Julius Wong who wrote (216315)	9/5/2025 6:46:14 AM
From: TobagoJack	Respond to of 217533

re <<turn>>

To: Julius Wong who wrote (216315)	9/5/2025 6:52:12 AM
From: TobagoJack	Respond to of 217533

re <<turn>> :0) bloomberg.com Tesla Offers Unprecedented $1 Trillion Pay Package to Musk Dana Hull September 5, 2025 at 6:45 PM GMT+8 Tesla Inc. proposed a new compensation agreement for Chief Executive Officer Elon Musk potentially worth around $1 trillion, a massive package without precedent in corporate America. The long-awaited proposal, designed to incentivize Musk to lead Tesla for years to come, sets a series of ambitious benchmarks he must meet to earn the full payout, including expanding Tesla’s robotaxi business and growing the company’s market value to at least $8.5 trillion from around $1 trillion today. The plan spans 10 years. The additional shares Musk could receive would push his stake in the electric-vehicle maker to at least 25%, according to the terms detailed in Tesla’s proxy filing Friday. Musk has publicly stated he wants a stake of that size. Elon Musk Photographer: Allison Robbert/AFP/Bloomberg The plan dangles afinancial windfall and expanded control of the company to Musk, already the world’s richest person, after his 2018 package valued in excess of $50 billion was struck down by a Delaware court. While Tesla appeals that decision, the board is seeking other ways to compensate its CEO, including with an interim stock award in early August valued at about $30 billion. The incentives in the new plan aim to keep Musk’s focus on Tesla while it pursues growth in newer markets including robotics and artificial intelligence. Friday’s filing also included a non-binding shareholder proposal for Tesla to take a stake in Musk’s xAI startup, an idea Musk has previously discussed. The new agreement underscores Musk’s iron grip on the automaker, despite the myriad demands on his time. Musk, who has served as Tesla’s top executive since 2008, oversees four other companies: SpaceX, xAI, Neuralink and the Boring Co. He told Bloomberg in an interview in May that he’s committed to still being at the helm of Tesla in five years. Tesla shares rose 2% as of 6:30 a.m. Friday in New York. The stock has fallen 16% this year. A market capitalization of $8.5 trillion would be more than double that of Nvidia Corp., currently the world’s most valuable company. Tesla’s value peaked in late 2024 at about $1.5 trillion. The value of the latest CEO award, at $87.8 billion in the filing, would swell to about $1 trillion if Musk hits all the performance targets and gets to collect all the restricted shares. The proxy also outlines that Musk must participate in the board’s development of a framework for long-term CEO succession in order to earn either of the last two tranches of the performance award. “Simply put, retaining and incentivizing Elon is fundamental to Tesla achieving these goals and becoming the most valuable company in history,” Tesla said in a shareholder letter signed by Chair Robyn Denholm and director Kathleen Wilson-Thompson. Competing Priorities Musk, 54, has previously urged the board to arrange a new compensation package for him, suggesting he would pursue artificial intelligence and robotics products elsewhere if he didn’t have roughly 25% voting control at Tesla. While Musk remains Tesla’s largest shareholder, he sold a significant portion of his stock to fund his acquisition of Twitter. The social-media platform, which he renamed X, was acquired by Musk’s xAI earlier this year. Tesla’s board is sticking with Musk despite his competing priorities. Besides overseeing other companies, his attention has increasingly turned to politics. He was President Donald Trump’s biggest financial backer in last year’s election and briefly led efforts to remake the federal government. This sparked a backlash against Tesla that included sporadic cases of arson and vandalism at stores and charging stations. The blowback contributed to a volatile first half, with Tesla reporting two of its worst quarters in years and a 13% decline in worldwide vehicle deliveries. Tesla vehicles at the company’s store in Warminster, Pennsylvania. Photographer: Joe Lamberti/Bloomberg Late May marked Musk’s last official day as a special government employee, and he committed to spending more time at Tesla. Only days later, he and Trump had a bitter falling-out. Tesla regained some momentum the last few months, rolling out its long-promised driverless-taxi service that Musk sees as an important part of its future business. The company launched June 22 with a handful of robotaxis in Austin. — With assistance from Kara Carlson, Catherine Larkin, and Anders Melin

To: Julius Wong who wrote (216315)	9/6/2025 2:33:31 AM
From: TobagoJack	Read Replies (1) \| Respond to of 217533

for this day re <<AI>> bloomberg.com OpenAI Says Spending to Rise to $115B Through 2029 By Yi Wei Wong September 6, 2025 at 10:34 AM GMT+8 OpenAI Inc. told investors it projects its spending through 2029 may rise to $115 billion, about $80 billion more than previously expected, The Information reported, without providing details on how and when shareholders were informed. OpenAI is in the process of developing its own data center server chips and facilities to drive the technologies, in an effort to control cloud server rental expenses, according to the report. The company predicted it could spend more than $8 billion this year, roughly $1.5 billion more than an earlier projection, The Information said. Another factor influencing the increased need for capital is computing costs, on which the company expects to spend more than $150 billion from 2025 through 2030. The cost to develop AI models is also higher than previously expected, The Information said.